バイオシミラー・モノクローナル抗体(MAb)の世界市場

◆英語タイトル:Biosimilar Monoclonal Antibodies: World Industry and Market Outlook 2015-2025
◆商品コード:VGAIN5020406
◆発行会社(調査会社):visiongain
◆発行日:2015年1月
◆ページ数:184
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:世界
◆産業分野:バイオ技術
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥242,865見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥404,865見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥674,865見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、バイオシミラー・モノクローナル抗体(MAb)の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・バイオシミラー・モノクローナル抗体(MAb)の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・有望製品分析
・地域別市場分析
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Biosimilar therapeutic antibodies – see why originator companies should now fear those competitors, discovering their trends and potential sales
What’s the future of biosimilar antibody therapies (mAbs)? Can that emerging market, with vast potential, achieve expected sales growth? See what’s likely there, staying ahead.

Now, in an updated study, you explore that industry’s research and development (R&D). And assess forecasted revenues. So discover where the money lies from 2015, hearing where those drug producers, their technologies and products head.

There avoid struggles to get business information. Instead read on to explore those companies and their medicines, also seeing how that industry’s sales can soon multiply.

Forecasts and other analysis to help your research, knowledge and influence
Visiongain’s new guide predicts those revenues to 2025 at overall world, class (molecule), product and national level. Its purpose is to help you stay ahead on companies, data, news, opportunities and analysis for those follow-on protein pharmaceuticals.

So examine developments underpinning those treatments’ future performance. Assess medical, technological and commercial trends, results and potentials:
• Why will the biosimilar mAbs market expand fast from 2015 to 2025, and what limits its sales growth?
• When will that industry achieve multibillion dollar revenues, and what’s possible?
• What compounds and products – follow-on biologics – give the most promise to developers, producers and sellers?
• Who are the best-placed companies for revenue generation there from 2015?
• Where lie the best geographical prospects for selling those biological drugs?
• How will companies approach opportunities and challenges in serving regulators, doctors, patients and payers?

Besides multilevel revenue predictions to 2025, our work presents historical results, market shares and discussions. You get 73 tables, 56 charts and four research interviews with companies and other authorities.

Advantages to make investigating those biologicals easier, also benefiting your knowledge
Developments worldwide expand the biosimilar mAbs market. Hear what’s possible.

Our new investigation speeds and facilitates your research, analysis and decisions on those competitors of original biopharmaceutical antibodies. See how. Let that study benefit your reputation for technological and commercial insight.

The following sections explain how that new analysis helps you.

Potentials of those medicines in that world market and its submarkets
Our new report shows revenue to 2025 for the overall world market. It also shows individual forecasts of six biosimilar mAb submarkets by molecule:
• Infliximab
• Rituximab
• Abciximab
• Trastuzumab
• Adalimumab
• Bevacizumab
• Other agents (grouped prediction).

How will the biosimilar mAbs market expand? Which parts will prosper most? Our study lets you assess prospects for revenue growth, seeing where the most lucrative opportunities lie.

There you also gain feel for what stimulates and restrains that industry and market. That analysis helps you spot commercial potentials and find ways for your business to develop.

You also discover revenue predictions for products using that follow-on antibody technology.

Forecasts for 16 medicines – potentials for existing and expected protein-based drugs?
How will products perform at world level to 2025? Our report forecasts individual revenues of 16 biosimilar antibodies, launched or expected, including these brands:
• Dr. Reddy’s Reditux
• Celltrion’s Remsima, Hospira’s Inflectra and Egis’s Flammegis
• Epirus Biopharmaceuticals’ Infimab
• Intas Pharmaceuticals’ Mabtas
• BIOCAD’s AcellBia
• Isu Abxis’ Clotinab
• Reliance Life Sciences’ AbcixiRel.

There you find how high sales can go, to 2025, exploring medications and years with highest predicted growth and revenues. You also examine competitors. You see what’s happening, understanding trends, competition, challenges and opportunities.

The study also divides its overall world forecast into geographical predictions.

National healthcare markets – what demand and sales for those biotech drugs?
In developed and developing countries, many opportunities for makers of those substitute biological drugs will occur from 2015 to 2025. See why, where and how.

Our analyses show you individual revenue forecasts to 2025 for 12 national markets:
• United States (US)
• Japan
• South Korea
• Germany, France, UK, Italy and Spain (EU5 countries)
• China, India, Brazil and Russia (BRIC nations).

There find the best revenue prospects. Product launches from 2015 to 2025 will change the commercial landscape. Discover how, seeing what affects that biologics segment.

Issues affecting biosimilar antibody development, production, marketing and selling
Our investigation also explains progress, events and forces affecting that industry and market from 2015, including these influences:
• Demand for biosimilars and rising production needs
• Research and development (R&D) for those protein-based medicines
• FDA biosimilar guidelines and state regulation of drug substitution
• Legal challenges for those substitute drugs.

And these issues, among others:
• Biobetters as a threat to biosimilars
• EMA regulations and drug approvals, and marketing controls in other regions
• Collaboration in follow-on mAb development
• Big pharma’s emergence into that market.

There explore political, economic, social and technological (SWOT) questions, assessing outlooks. You also analyse that industry’s strengths, weaknesses, opportunities and threats (SWOT forces). See, then, what the future holds.

So discover the potential of agents challenging innovator biopharmaceuticals. See what happens after patent exclusivity on the original brands expires. And examine how competitors prepare for those opportunities. The possibilities are vast.

Biosimilar antibody-based therapies – what’s their future market value?
What happens next? Our study predicts the overall world market for biosimilar mAbs will exceed $4bn by 2020, multiplying in value many times from 2015 to 2025.

For original biological drugs, high threats from biosimilar competition exist. See, then, which companies are best placed to succeed in that huge potential market for substitute products.

Investigate the actions and potential of these and other participants:
• BioXpress
• Celltrion
• Harvest Moon
• Genor Biopharma
• Mabion
• Gene Techno Science
• Biocon
• Pfizer
• BIOCAD.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Biosimilar Monoclonal Antibodies
1.2 Why You Should Read This Report
1.3 How This Study Delivers
1.4 Main Questions Answered by the Analysis
1.5 Who Is This Investigation For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Biosimilar Monoclonal Antibodies
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.3 Humanising the MAb
2.4 Biologics (Biological Drugs) and Biosimilars
2.5 Why are Biosimilars in High Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Much a Concern is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies on the Market

3. World Market Prospects for Biosimilar Monoclonal Antibodies, 2015-2025
3.1 The World Market for Biosimilar Monoclonal Antibodies, 2013- 2014: Three Biosimilar MAbs on Sale
3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2014-2025
3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2019 and 2025
3.4 The World Market for Biosimilar MAbs by Compound: Revenue Forecasts, 2014-2025
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: High Growth Expected
3.4.2.1 Biosimilar Infliximab: Revenue Forecast, 2015-2025
3.4.3 Biosimilar Rituximab: With Many Compounds Under Development, Will Sales Growth be Driven or Restrained?
3.4.3.1 Biosimilar Rituximab: Revenue Forecast, 2015-2025
3.4.4 Biosimilar Abciximab: Low Market Incentive Means Few Compounds in Development
3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2015-2025
3.4.5 Biosimilar Trastuzumab: The 4th Biosimilar MAb to Enter the Market
3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2015-2025
3.4.6 Biosimilar Adalimumab: Great Incentive to Develop Biosimilar Versions of the Leading Drug of 2013 & 2014
3.4.6.1 Biosimilar Adalimumab: Revenue Forecast, 2015-2025
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Market Restrict Revenue Generation?
3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2015-2025
3.5 Large Market Potential to Drive Growth to 2025
3.6 What Will Restrain Expansion of the Biosimilar MAbs Market Between 2013 and 2025?

4. Promising Biosimilar MAb Products and Their Predicted Future Successes, 2015-2025
4.1 Biosimilar Versions on the Market: Remsima Dominated in 2013
4.1.1 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.2 Dr. Reddy’s Reditux (rituximab): Are US and EU Approval Expected?
4.1.3 Isu Abxis’ Clotinab (abciximab): The First Biosimilar Monoclonal Antibody?
4.1.4 Instas Pharmaceuticals’ Mabtas (Rituximab)
4.1.5 Reliance Life Sciences’ AbcixiRel (abciximab)
4.1.6 Probiomed’s Kikuzubam (rituximab): Registration Revoked, Reports Suggest
4.2 Biosimilar Versions on the Market and Promising Compounds in the R&D Pipeline: Revenue Forecasts, 2015-2025
4.2.1 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): Revenue Forecast, 2015-2025
4.2.2 Epirus Biopharmaceuticals’ Infimab (infliximab): Revenue Forecast, 2014-2025
4.2.3 Dr. Reddy’s Reditux (rituximab): Revenue Forecast, 2015-2025
4.2.4 Intas Pharmaceuticals’ Mabtas (rituximab): Revenue Forecast, 2015-2025
4.2.5 BIOCAD’s AcellBia (rituximab): Revenue Forecast, 2015-2025
4.2.6 Boehringer Ingelheim’s BI695500 (rituximab): Revenue Forecast, 2015-2025
4.2.7 Celltrion’s CT-P10 (rituximab): Revenue Forecast, 2015-2025
4.2.8 Isu Abxis’ Clotinab (abciximab): Revenue Forecast, 2015-2025
4.2.9 Reliance Life Sciences’ AbcixiRel (abciximab): Revenue Forecast, 2015-2025
4.2.10 Biocon and Mylan’s CANMAb/Hertraz (trastuzumab): Revenue Forecast, 2015-2025
4.2.11 Celltrion’s Herzuma (trastuzumab): Revenue Forecast, 2015-2025
4.2.12 BIOCAD’s BCD-022 (trastuzumab): Revenue Forecast, 2015-2025
4.2.13 Boehringer Ingelheim’s BI695501 (adalimumab): Revenue Forecast, 2015-2025
4.2.14 Fujifilm Kyowa Kirin Biologics’ FKB327 (adalimumab): Revenue Forecast, 2015-2025
4.2.15 BIOCAD’s BCD-021 (bevacizumab): Revenue Forecast, 2015-2025
4.2.16 Fujifilm Kyowa Kirin Biologics’ FKB238: Revenue Forecast, 2015-2025

5. Leading National Markets for Biosimilar Monoclonal Antibodies, 2015-2025
5.1 What Were the Leading National Markets for Biosimilar Monoclonal Antibody Development in 2013?
5.2 What Were the Leading National Markets for Sales of Biosimilar Monoclonal Antibodies in 2013?
5.3 Which Markets Will Grow Fastest to 2025?
5.4 Market Shares of the Leading National Markets: All Set to Change, 2015-2025
5.5 South Korea: The World’s Leading Nation for Biosimilar MAbs
5.5.1 KFDA Introduced Biosimilar Guidelines in 2009
5.5.2 Significant Investment in Biosimilars in South Korea
5.5.3 Outlook for the South Korean Biosimilar MAb Market, 2014-2025
5.6 The Outlook for Monoclonal Antibody Biosimilars in China, 2015-2025
5.6.1 China to Release Formal Biosimilar Development Guidelines
5.6.2 China: Becoming the World’s Leading Market for Biosimilar MAbs
5.7 Brazil: The Third Leading Country in the 2013 Biosimilar MAb Market, But What Does The Future Hold?
5.7.1 ANVISA’s Biosimilar Regulations Are Similar to the EMA’s
5.7.2 Outlook for Monoclonal Antibody Biosimilars in Brazil, 2015-2025
5.8 Outlook for Monoclonal Antibody Biosimilars in India, 2015-2025
5.8.1 India Releases New Biosimilar Development Guidelines
5.8.2 Indian Biosimilars Submarket Forecast 2015-2025
5.9 The Outlook for Biosimilar MAbs in the US, 2015-2025
5.9.1 When Are the Final FDA Biosimilar Guidelines Expected?
5.9.2 Legal Challenges for Biosimilars in the US
5.9.3 State Regulation of Biosimilar Substitution
5.9.4 The US Biosimilar MAb Market: Revenue Forecast, 2015-2025
5.10 The Outlook for Monoclonal Antibody Biosimilars in Japan 2015-2025
5.10.1 Regulatory Processes for Biosimilars in Japan
5.10.2 Regulations for Naming Biosimilars
5.10.3 Biosimilar MAbs to be Launched in Japan in 2016
5.10.4 Japanese Biosimilar Submarket Forecast 2015-2025
5.11 The Outlook for Monoclonal Antibody Biosimilars in the EU, 2015-2025
5.11.1 The EU Led the World in Biosimilar Regulation
5.11.2 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar MAbs
5.11.3 EMA Simplifies Biosimilar Development in the EU
5.11.4 Biosimilar MAbs in the EU5 Countries: Revenue Forecasts, 2015-2025
5.11.5 Germany: Set to Become the Largest National Market for Biosimilar MAbs in the EU
5.11.6 France: Will the Uptake of Biosimilar MAbs Be Restricted?
5.11.7 UK: Drug Uptake Will Be High
5.11.8 Italy: Healthcare Spending Cuts Will Drive Growth
5.11.9 Spain: High Biosimilar MAb Discounts Expected
5.12 The Outlook for Monoclonal Antibody Biosimilars in Russia, 2015-2025
5.12.1 No Specific Biosimilar Legislation Exists in Russia, 2014
5.12.2 Russian Government Investing in Development of Biosimilars
5.12.3 Russian Biosimilar MAb Revenue Forecast 2015-2025

6. Leading Companies for Developing and Producing Biosimilar MAbs
6.1 Prominent Companies in the Biosimilar Monoclonal Antibodies Industry, 2014
6.2 Collaboration in Biosimilar MAb Development
6.3 BioXpress: 16 Compounds in the R&D Pipeline
6.4 Celltrion: One Compound on the Market and Two in Phase III of Development, and Others Wait In The Wings
6.5 Harvest Moon: Six Compounds Under Development
6.6 Genor Biopharma: Five Compounds in Development
6.7 Mabion: Poland’s Leading Biosimilar MAb Developer
6.8 Gene Techno Science: Three Compounds Under Development
6.9 India’s Biocon: A Quiet Competitor
6.10 Pfizer: Entering the Biosimilar MAbs Industry and Market
6.11 BIOCAD: Company Based in Russia
6.12 Big Pharma and the Biosimilar MAbs Market

7. Qualitative Analyses of the Biosimilar MAbs Market, 2015-2025
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2014
7.1.1 Worldwide Demand for More-Affordable Therapies Underpins that Market
7.1.2 Complexity of Protein Molecules Gives Technical Challenges
7.2 Opportunities and Threats Facing the Biosimilar Monoclonal Antibody Market, 2015-2025
7.2.1 A Well-Stocked Pipeline in the Face of Approaching Patent Expiries: Opportunities for Market Expansion
7.2.2 Competition and Lack of Confidence: Threats to Market Penetration?
7.2.2.1 Biobetters as a Threat to Biosimilars
7.3 Social, Technological, Economic and Political Forces Influencing the Biosimilar Monoclonal Antibodies Market (STEP Analysis) 2015-2025
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Advances in Technology: Producing Biosimilar MAbs Cheaply and Easily
7.3.3 Economic Pressures Raise Demand for Biosimilar MAbs
7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry

8. Research Interviews from Our Survey
8.1 Interview with Bruce Burnett
8.1.1 On Regulations for and Testing of Biosimilars
8.1.2 On Drivers and Restraints for Biosimilar MAbs
8.1.3 Biosimilars and Immunogenicity
8.1.4 On Biosimilars and Research
8.2 Interview with Dr Corrine SinQuee-Brown, The Cancer Center Bahamas
8.2.1 On Biosimilar MAbs in The Bahamas
8.2.2 On Drivers and Restraints for Biosimilar MAbs
8.3 Interview with Dr Xing Wang, President of Array Bridge
8.3.1 On Challenges Surrounding the Development of Biosimilar MAbs
8.3.2 On the Services Offered by Array Bridge
8.3.3 On the Demand for Biosimilar MAbs
8.3.4 On Factors Determining the Success of Biosimilar MAbs
8.3.5 On Regulatory Approval of Biosimilar MAbs: The US vs. the EU
8.4 Interview With Dr Terence Ryan, SVP, iBio
8.4.1 iBio and its Biosimilar Pipeline, 2013
8.4.2 The iBioLaunch Platform
8.4.3 Differences Between Developing Biosimilar and Biologics
8.4.4 Product Differentiation in the Biosimilar Market
8.4.5 Biosimilars and Immunogenicity
8.4.6 Challenges in Developing Biosimilars for the US Market

9. Conclusions from the Research and Analysis
9.1 Biosimilar Monoclonal Antibodies: World Market, 2015-2025
9.2 The Future of Top Compounds in Development and Testing
9.3 Leading National Markets for Biosimilar Monoclonal Antibodies, 2015-2025
9.4 Leading Companies in the Industry
9.5 Trends in the Industry and Market
9.5.1 Economic Pressures Stimulate Demand for Therapeutic MAbs
9.5.2 Patent Expiries of Several Blockbuster MAbs Are Approaching, Creating Large Opportunities for Biosimilars
9.5.3 Complexity of the Molecules Make Production Challenging
9.5.4 Doctor and Patient Doubt Regarding Interchangeability Will Restrict Uptake
9.5.5 Do Biobetters Pose a Threat?

List of Tables
Table 1.1 Submarket Forecasts of Biosimilar MAbs, 2014-2025
Table 1.2 Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Classification of Monoclonal Antibodies
Table 2.2 Murine Monoclonal Antibodies on the Market, 2013
Table 2.3 Chimeric Monoclonal Antibodies on the Market, 2013
Table 2.4 Humanised Monoclonal Antibodies on the Market, 2013
Table 2.5 Fully Human Monoclonal Antibodies on the Market, 2013
Table 2.6 Top 10 Prescription Drugs by Revenue ($bn), 2013
Table 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Revenue ($m) and Market Share (%), 2013
Table 3.2 Biosimilar MAb World Market: Revenue Forecast ($m), 2014-2025
Table 3.3 The World Market for Biosimilar MAbs: Revenues ($m) and Market Shares (%) by Compound, 2013, 2019 and 2025
Table 3.4 Prominent Originator Biologic Products: EU and US Patent Expiry Dates
Table 3.5 Biosimilar MAbs: World Revenue Forecasts ($m) by Molecule, 2014-2025
Table 3.6 Biosimilar Infliximab: Compounds in the R&D Pipeline, 2014
Table 3.7 Biosimilar Infliximab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.8 Biosimilar Rituximab: Compounds in the Pipeline, 2014
Table 3.9 Biosimilar Rituximab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.10 Biosimilar Abciximab: Compounds in the Pipeline, 2014
Table 3.11 Biosimilar Abciximab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.12 Biosimilar Trastuzumab: Compounds in the Pipeline, 2014
Table 3.13 Biosimilar Trastuzumab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.14 Biosimilar Adalimumab: Compounds in Development, 2014
Table 3.15 Biosimilar Adalimumab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 3.16 Biosimilar Bevacizumab: Compounds in the Pipeline, 2014
Table 3.17 Biosimilar Bevacizumab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.1 Biosimilar MAb Versions on the Market: Revenues ($m) and Market Shares (%), 2013
Table 4.2 Biosimilar Versions on the Market and in the Pipeline: Revenue Forecasts ($m), 2014-2025
Table 4.3 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.4 Epirus Biopharmaceuticals' Infimab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.5 Dr. Reddy’s Reditux: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.6 Intas Pharmaceuticals’ Mabtas: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.7 BIOCAD’s AcellBia: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.8 Boehringer Ingelheim's BI695500: Revenue Forecast, 2014-2025
Table 4.9 Celltrion's CT-P10: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.10 Isu Abxis' Clotinab: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.11 Reliance Life Sciences’ AbcixiRel: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.12 CANMAb/Hertraz: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.13 Celltrion's Herzuma: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.14 BIOCAD's BCD-022: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.15 Boehringer Ingelheim's BI695501: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.16 Fujifilm Kyowa Kirin Biologics' FKB327: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.17 BIOCAD’s BCD-021: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 4.18 Fujifilm Kyowa Kirin Biologics' FKB238: Revenue ($m) and Market Share (%) Forecast, 2014-2025
Table 5.1 Prominent Companies with 2+ Biosimilar MAbs in Development and Their Country of Origin, 2013
Table 5.2 The Biosimilar MAb Market by Country: Revenues ($m) and Market Shares (%), 2013
Table 5.3 The Biosimilar MAb Market by Country: Grouped Revenue Forecasts ($m), 2014-2025
Table 5.4 The Biosimilar MAb Market: National Market Shares (%), 2013-2025
Table 5.5 The South Korean Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.6 The Chinese Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.7 The Brazilian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.8 The Indian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.9 The US Biosimilar MAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2014-2025
Table 5.10 The Japanese Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.11 EU5 Biosimilar MAb Markets: Overall Revenue ($m), Annual Growth (%) and CAGR (%) Forecasts by Country, 2014-2025
Table 5.12 The German Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.13 The French Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.14 The UK Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.15 The Italian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.16 The Spanish Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 5.17 The Russian Biosimilar MAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2014-2025
Table 6.1 Companies in the Biosimilar MAb Industry by Number of Compounds in Development, 2014
Table 6.2 Selected Collaborations for Biosimilar MAb Development, 2009-2014
Table 6.3 BioXpress: Compounds in the Pipeline, 2014
Table 6.4 Tests Carried Out By BioXpress During Biosimilar MAb Development, with Objectives
Table 6.5 Compounds in Celltrion’s Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2013
Table 6.6 Genor Biopharma: Biosimilar MAbs Pipeline, 2014
Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2014
Table 6.8 Gene Techno Science: Revenue and Gross Profit ($m), Year Ended March 2012 and 2013
Table 6.9 Biocon: Compounds in the Pipeline and Their Stage of Development, 2014
Table 6.10 Pfizer: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.11 BIOCAD: Compounds in the Pipeline and Their Stage of Development, 2013
Table 6.12 Big Pharma's Positions in the Biosimilar MAb Industry, 2013
Table 7.1 Strengths and Weaknesses of the Biosimilar MAb Market, 2015
Table 7.2 Opportunities and Threats Facing the Biosimilar MAb Market, 2015-2025
Table 7.3 Social, Technological, Economic and Political Factors Influencing the Biosimilar MAb Market (STEP Analysis), 2015-2025

List of Figures
Figure 1.1 Selected Biosimilar MAbs: Main Compound Classes, 2014
Figure 2.1 Structure of an Antibody
Figure 3.1 The Biosimilar Monoclonal Antibody Market by Compound: Market Share (%), 2013
Figure 3.2 The World Market for Biosimilar MAbs: Revenue Forecast ($m), 2014-2025
Figure 3.3 The Biosimilar MAb Market: Market Share (%) by Compound, 2019
Figure 3.4 The Biosimilar MAb Market: Market Share (%) by Compound, 2025
Figure 3.5 Biosimilar Infliximab: Revenue Forecast ($m), 2014-2025
Figure 3.6 Biosimilar Rituximab: Revenue Forecast ($m), 2014-2025
Figure 3.7 Biosimilar Abciximab: Revenue Forecast ($m), 2014-2025
Figure 3.8 Biosimilar Trastuzumab: Revenue Forecast ($m), 2014-2025
Figure 3.9 Biosimilar Adalimumab: Revenue Forecast ($m), 2014-2025
Figure 3.10 Biosimilar Bevacizumab: Revenue Forecast ($m), 2014-2025
Figure 3.11 Biosimilar MAbs: Market Drivers and Restraints, 2014-2025
Figure 4.1 Biosimilar MAb Versions on the Market: Market Share (%), 2013
Figure 4.2 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2019
Figure 4.3 Biosimilar MAb Versions on the Market and in the Pipeline: Market Shares (%), 2025
Figure 4.4 Celltrion’s Remsima / Hospira’s Inflectra / Egis’ Flammegis (infliximab): Revenue Forecast ($m), 2014-2025
Figure 4.5 Epirus Biopharmaceuticals' Infimab: Revenue Forecast ($m), 2014-2025
Figure 4.6 Dr. Reddy’s Reditux: Revenue Forecast, 2014-2025
Figure 4.7 Intas Pharmaceuticals’ Mabtas Revenue Forecast ($m), 2014-2025
Figure 4.8 BIOCAD’s AcellBia: Revenue Forecast ($m), 2014-2025
Figure 4.9 Boehringer Ingelheim's BI695500: Revenue Forecast, 2014-2025
Figure 4.10 Celltrion's CT-P10: Revenue Forecast ($m), 2014-2025
Figure 4.11 Isu Abxis' Clotinab: Revenue Forecast ($m), 2014-2025
Figure 4.12 Reliance Life Sciences' AbcixiRel: Revenue Forecast ($m), 2014-2025
Figure 4.13 CANMAb/Hertraz: Revenue Forecast ($m), 2014-2025
Figure 4.14 Celltrion's Herzuma: Revenue Forecast, 2014-2025
Figure 4.15 BIOCAD's BCD-022: Revenue Forecast ($m), 2014-2025
Figure 4.16 Boehringer Ingelheim's BI695501: Revenue Forecast ($m), 2014-2025
Figure 4.17 Fujifilm Kyowa Kirin Biologics' FKB327: Revenue Forecast ($m), 2014-2025
Figure 4.18 BIOCAD’s BCD-021 Revenue Forecast ($m), 2014-2025
Figure 4.19 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast ($m), 2014-2025
Figure 5.1 Geographical Distribution (%) of Prominent Compounds under Development, 2014
Figure 5.2 The Biosimilar MAb Market by Country: Market Shares (%) of Revenue, 2014
Figure 5.3 The Biosimilar MAb Market: National Submarket Shares (%), 2019
Figure 5.4 The Biosimilar MAb Market: National Submarket Shares (%), 2025
Figure 5.5 The South Korean Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.6 The Chinese Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.7 The Brazilian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.8 The Indian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.9 FDA Biosimilar Guidelines: Key Points
Figure 5.10 Biosimilar MAbs in the US: Revenue Forecast ($m), 2014-2025
Figure 5.11 The Japanese Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.12 The EU5 Biosimilar MAb Market: Grouped Revenue Forecast ($m), 2014-2025
Figure 5.13 The EU5 Biosimilar MAb Market: Revenue Forecasts ($m) by Country, 2014-2025
Figure 5.14 The German Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.15 The French Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.16 The UK Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.17 The Italian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.18 The Spanish Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 5.19 The Russian Biosimilar MAb Market: Revenue Forecast ($m), 2014-2025
Figure 6.1 Prominent Companies in the Biosimilar MAb Industry: Share (%) of the Pipeline, 2014
Figure 9.1 Prominent Compounds in the Biosimilar MAb Market: Comparison of Revenues ($m), 2013, 2019 and 2025
Figure 9.2 Promising Versions of Biosimilar MAbs: Comparison of Revenues ($m), 2013, 2019 and 2025
Figure 9.3 Leading National Markets: Revenues ($m), 2013, 2019 and 2025
Figure 9.4 Prominent Companies in the Biosimilar MAb Industry: Number of Products in the Pipeline, 2013

【掲載企業】

Abbott Laboratories
AbbVie
Aché
Actavis
AET BioTech
Agência Nacional de Vigilância Sanitária (ANVISA)
Alexion Pharmaceuticals
Alvogen
Alvotech
Amgen
Aprogen
Array Bridge
AstraZeneca
Bayer
BIO
BIOCAD
Biocon
Biogen Idec
Bio-Manguinhos
Bionovis
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Celltrion
Celon Pharma Łomianki
Coherus BioSciences
Cour des Comptes (France)
Daiichi Sankyo
Dong-A
Dr. Reddy’s Laboratories
Egis Pharmaceuticals
Eli Lilly
Emcure
EMS
Epirus Biopharmaceuticals
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Fraunhofer Center for Molecular Biology
Fresenius
Fujifilm Kyowa Kirin Biologics
Gedeon Richter
Gene Techno Science
Genentech
Genexo
Genor Biopharma
GlaxoSmithKline (GSK)
Glycotope
Hanwha Chemical
Harvest Moon
Health Canada
Hospira
Hypermarcas
iBio
IBSS Biomed
ImClone LLC
Instas Pharmaceuticals
Instituto Vital Brazil
IPCA Labs
Isu Abxis
Janssen
Johnson & Johnson
Korean Food and Drug Administration (KFDA)
Kyowa Hakko Kirin
Laboratorios Liomont
LG Life Sciences
Lonza
Mabion
mAbxience
Medicines and Healthcare Products Regulatory Agency (MHRA)
MedImmune
Merck & Co.
Merck Serono
Millhouse LLC
Ministry of Health (Russia)
Ministry of Health, Labour and Welfare (MHLW)
Mitsubishi Tanabe
Mochida Pharmaceutical
Mustafa Nevzat Pharmaceuticals
Mylan
Natco Pharma
National Institute for Health and Care Excellence (NICE)
Nichi-Iko Pharmaceutical Co.
Nippon Kayaku
Novartis
Oncobiologics
Otsuka Pharmaceutical
Parexel
Pfizer
PharmaPraxis
Pharmstandard
PhRMA
PlantForm
Polfarmex
Probiomed
Quintiles
Reliance Life Sciences
Roche
Samsung Bioepis
Sandoz
Sanofi
Schnell
Scientific Centre for Expertise of Medicinal Application Products (Russia)
Seattle Genetics
Shanghai CP Guojian
Shionogi
Spectrum Pharmaceuticals
Stada
State Food and Drug Administration (SFDA)
Synthon
Takeda
Teva Pharmaceutical Industries
The Cancer Centre Bahamas
UCB
União Química
Viropro
Walvax Biotechnology
World Health Organization (WHO)
Wyeth
Zenotech
Zhejiang Huahai Pharmaceutical

【レポートのキーワード】

バイオシミラー・モノクローナル抗体(MAb)、バイオ後続品、製薬

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[バイオシミラー・モノクローナル抗体(MAb)の世界市場]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年09月29日現在 207,700 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆